To evaluate the impact of perfluorohexyloctane ophthalmic solution (PFHO) on preoperative biometry and dry eye symptoms in cataract surgery patients.
Key Findings:
PFHO treatment did not negatively affect refractive outcomes; 82.6% of patients were within ±0.50 diopters of predicted refraction after treatment.
Total corneal fluorescein staining improved significantly, with 75.8% of patients showing no central corneal staining after 30 days of PFHO therapy.
Eye dryness scores improved from 62.3 to 25.9, and OSDI scores normalized from 51.9 to 11.9 by the end of the study.
IOL calculation accuracy improved, with 84% of patients within ±0.5 diopters post-treatment compared to 72% at baseline.
Best-corrected visual acuity (BCVA) of 20/20 or better increased from 86% to 92% after the postoperative treatment period.
Interpretation:
PFHO effectively treats dry eye disease without compromising critical measurements for cataract surgery, enhancing both ocular surface health and visual outcomes.
Limitations:
The study may benefit from a larger patient population and an untreated control arm.
Long-term outcomes beyond the 60-day follow-up period were not assessed.
Conclusion:
Aggressive treatment of dry eye with PFHO can improve patient comfort and surgical outcomes in cataract surgery, emphasizing the importance of ocular surface optimization.
